Vascular Endothelial Growth Factor A isoform mRNA expression in pediatric acute myeloid leukemia

Pediatric Blood and Cancer

Volumn 56, Issue 2, 2011, Pages 294-297

  Kruizinga, R C ^a,b   De Jonge, H J M ^a   Kampen, K R ^a   Walenkamp, A M E ^b   De Bont, E S J M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

AML; Isoform; VEGFA

Indexed keywords

MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; FEMALE; GENE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE FREE SURVIVAL; VEGF121 GENE; VEGF145 GENE; VEGF148 GENE; VEGF165 GENE; VEGF183 GENE; VEGF189 GENE; VEGFA GENE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; PROGNOSIS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78650138258     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22783     Document Type: Article

References (19)

1. de Bont ES, Fidler V, Meeuwsen T, et al. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 2002; 8: 2856-2861.
2. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3717-3721.
3. de Bont ES, Rosati S, Jacobs S, et al. Increased bone marrow vascularization in patients with acute myeloid leukaemia: A possible role for vascular endothelial growth factor. Br J Haematol 2001; 113: 296-304.
4. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
5. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103: 159-165.
6. Watanabe Y, Lee SW, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 1997; 14: 2025-2032.
7. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039.
8. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954-958.
9. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 2004; 103: 3883-3889.
10. Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106: 511-521.
11. Houck KA, Ferrara N, Winer J, et al. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5: 1806-1814.
12. Neufeld G, Cohen T, Gitay-Goren H, et al. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev 1996; 15: 153-158.
13. Ruhrberg C, Gerhardt H, Golding M, et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002; 16: 2684-2698.
14. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
15. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
16. de Jonge HJ, Weidenaar AC, Ter EA, et al. Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia. Clin Cancer Res 2008; 14: 924-930.
17. Stalmans I, Ng YS, Rohan R, et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 2002; 109: 327-336.
18. Lee S, Jilani SM, Nikolova GV, et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005; 169: 681-691.
19. Zhang HT, Scott PA, Morbidelli L, et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 2000; 83: 63-68.